Gather additional industry and technical information from our repository of resources and educational content.

Filter 142 Results

Application
Technology
Service
Content Type

Micro-Dosing and Powder-in-Capsule Evaluations

Lonza's leadership in powder-in-capsule (PIC) development using our Xcelodose® precision powder micro-dosing systems technology spans more than 200 active pharmaceutical ingredients (APIs) and more than 600 batches. This micro-dosing platform and extensive expertise can help customers accelerate initial studies to determine if an API should be advanced for further investment and investigation. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Lonza Nansha, China for Global Excellence in Advanced Chemical Synthesis

This brochure provides an overview of the extensive capabilities for small molecule manufacturing and advanced chemical synthesis available at Lonza's manufacturing site at Nansha, China. This state-of-the-art facility is FDA registered and builds on Lonza's 40 years of experience in custom manufacturing. To learn more, please see our brochure.
Publish Date: 05-May-2020

Liquid-Fill Hard Capsule Technology

This technical brief describes Lonza's liquid-fill hard capsule (LFHC) technology, which provides a unique, flexible dosage form with a proven track record for addressing complex formulation challenges. Gelatin and HPMC (hypromellose) hard capsules are available with different sealing options for liquid, semi-solid, paste, and multiparticulate applications, providing secure protection for active compounds through leakproof, airtight encapsulation impermeable to moisture, oxygen, and light. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Spray-Dried Dispersion Technology

With more than 20 years of formulation and manufacturing expertise, Lonza's spray-dried dispersion (SDD) platform incorporations compositions, processes, and dosage forms designed and proven to enhance bioavailability and the delivery of solid dosage forms. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Softgels

This technical brief describes Lonza's unique one-piece softgel capsule technology that can be used to deliver a wide range of formulation types and excipients. These capsules feature an easy-to-swallow shell that meets all global quality standards, as well as a tamper-resistant shell that masks taste and smell. The capsules are available in a wide range of unique shapes and colors to meet branding, line extension, and life-cycle management objectives. To learn more, please read our technical brief.
Publish Date: 05-May-2020

Taste-masking for Enhanced Oral Delivery

Taste-masking technologies offer huge benefits in patient compliance but meeting diverse product specifications in a narrow formulation space can be difficult. This technical brief describes the array of specialized taste-masking technologies and formulation approaches Lonza uses to address the bitter taste of many drugs, combining industry-leading expertise in innovative taste-masking approaches with enabling technologies. To learn more, please read our technical brief.
Publish Date: 05-May-2020

Solid Dosage Manufacturing, Packaging and Distribution

Solid dosage form manufacturing, packaging, and distribution can be key steps in getting products to market. Lonza offers integrated, full-service capabilities in these areas, which can help expedite product development timelines, reduce the risks associated with managing multiple partners, and accelerate speed to clinic and product commercialization. Product design, development, and manufacturing sites worldwide produce a full range of oral dosage forms in current Good Manufacturing Practice (cGMP) environments for clinical and commercial supply. To learn more, please see our technical brief.
Publish Date: 05-May-2020

Extended and Dual Release Technologies

Extended release (ER) is often needed or desired to deliver crystalline and solubilized forms of compounds. This technical brief describes two proprietary osmotic technologies offered by Lonza for ER formulations--asymmetric membrane technology (AMT) and swellable core technology (SCT)--which can be used alone or in combination with other modified-release technologies. To learn more, please read our technical brief.
Publish Date: 05-May-2020

SimpliFiH® Solutions

This technical brief describes Lonza's SimpliFiH Solutions--a streamlined, comprehensive service package designed for early-phase projects. Builiding our world-class expertise in bioavailability enhancement, SimpliFiH is designed to be a phase-appropriate solution in advancing drug programs to first-in-human (FIH) studies in as little as 32 weeks while reducing active-compound consumption, risk, and complexity. To learn more, please read our technical brief.
Publish Date: 05-May-2020

Lipid Multiparticulate Technology

Lipid multiparticulate (LMP) technology has the capacity to combine a breadth of functionality with a range of finished dosage formats: capsules, sachets, suspensions and tablets. This technical brief describes Lonza's novel LMP technology, which is based on a proprietary melt-spray-congeal process. This innovative drug delivery approach, which has market precedence, can be used for taste-masking, extended release, and bioavailability enhancement for pharmaceutical, health and nutritional products. To learn more, please read our technical brief.
Publish Date: 05-May-2020